Literature DB >> 11532545

QT dispersion within the first 6 months after an acute myocardial infarction: relationship with systolic function, left ventricular volumes, infarct related artery status and clinical outcome.

V Bodí1, J Sanchis, A Navarro, E Plancha, F J Chorro, A Berenguer, L Insa, P Escriche, F Cabadés, A Llácer.   

Abstract

INTRODUCTION: We analysed QT dispersion within the first 6 months postinfarction, its relationship with the main established risk stratifiers and its clinical value. METHODS AND
RESULTS: In 55 patients with a first Q-wave myocardial infarction the 12-lead electrocardiogram was scanned and digitised for analysis of QT dispersion (QT maximum-QT minimum) at first day (72 [61-96] ms), first week (69 [47-90] ms), first month (67 [46-88] ms) and sixth month (47 [40-74] ms; P<0.0001 vs. first day). Cardiac catheterization was performed at first week and at sixth month; QT dispersion was not related to ejection fraction, left ventricular volumes, infarct related artery status or contractile reserve (improvement of the infarcted area with low-dose dobutamine); no relation was found between QT dispersion decrease from first week to sixth month with regional systolic function improvement. Finally, during a mean follow-up period of 35+/-22 months QT dispersion was not independently related to clinical events.
CONCLUSION: QT dispersion decreases progressively during the first months after myocardial infarction. These changes should be taken into account to define cut-off values of clinical interest in this phase. This variable does not seem related to the classic prognosis predictors. In a nonselected postinfarction population it has a low clinical value.

Entities:  

Mesh:

Year:  2001        PMID: 11532545     DOI: 10.1016/s0167-5273(01)00452-1

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  Regional QT Interval Dispersion as an Early Predictor of Reperfusion in Patients with Acute Myocardial Infarction after Fibrinolytic Therapy.

Authors:  Gabriel Dotta; Francisco Antonio Helfenstein Fonseca; Maria Cristina de Oliveira Izar; Marco Tulio de Souza; Flavio Tocci Moreira; Luiz Fernando Muniz Pinheiro; Adriano Henrique Pereira Barbosa; Adriano Mendes Caixeta; Rui Manoel Santos Póvoa; Antônio Carlos Carvalho; Henrique Tria Bianco
Journal:  Arq Bras Cardiol       Date:  2018-12-17       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.